← Search & browse all drugs
RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › Leukotriene receptor antagonists
pranlukast
R03DC02
Forms & Strengths
- Dry syrup: 10% (100 mg/g)
- Capsule/Tablet: 112.5 mg
- Capsule/Tablet: 225 mg
Adult Dosing
- Asthma: 225 mg orally twice daily, taken in the morning and evening after meals
Pediatric Dosing
- Children 7 years and older: 112.5 mg orally twice daily after meals
- Children 1 to 6 years (dry syrup): 7 mg/kg body weight twice daily after meals (maximum single dose not to exceed adult dose)
Mechanism of Action
- Selective and competitive antagonist of the cysteinyl leukotriene receptor type 1 (CysLT1), inhibiting bronchoconstriction and inflammation induced by leukotrienes C4, D4, and E4
Contraindications
- Hypersensitivity to pranlukast or any component of the formulation
- Patients with severe hepatic impairment (due to metabolism and potential for hepatotoxicity)
Adverse Reactions
- Gastrointestinal: nausea, vomiting, abdominal pain, diarrhea
- Hepatic: elevated AST, ALT, and ALP, drug-induced liver injury, jaundice
- Dermatologic: rash, pruritus
- Nervous system: headache, dizziness
- Hematologic: leukopenia, thrombocytopenia (rare)
Drug Interactions
- CYP3A4 substrates: pranlukast is metabolized by CYP3A4 and may weakly inhibit CYP3A4, potentially increasing levels of co-administered substrates
- Warfarin: potential enhancement of anticoagulant effect (monitor INR)
Curated Content: Needs Vetting Before Put to Clinical Use